Clinical trial · Observational
Longitudinal Assessment of Health-Related Quality of Life in Men With Localized Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to assess quality-of-life of men with prostate cancer. "Quality-of-life" means how you feel about your life as a result of your disease and its treatment. The investigators hope that this questionnaire will help show how prostate cancer treatments affect quality-of-life. It will help doctors and future patients to make better treatment choices. Some men may wish to have a more demanding treatment with a higher risk of harmful effects. Others may prefer a treatment that will have the smallest effect on their quality-of-life. This questionnaire will help us measure these effects and decide which is the best treatment for a given patient.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Interview | Behavioral | — | UNRESOLVED |
| survey instruments using Web-Based Data Collection System (WBDC) survey content | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- Men with prostate cancer
- interventionNames
- Behavioral: Interview
- label
- 2
- description
- Men with prostate cancer
- interventionNames
- Behavioral: survey instruments using Web-Based Data Collection System (WBDC) survey content
Primary outcomes (1)
- measure
- Assessment of temporal trends in HRQOL according to intervention group
- timeFrame
- study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment)and between 60 and 96 months.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * diagnosis of localized, untreated prostate cancer (clinical stages T1-3, Nx, M0) * ability to read the English language Exclusion criteria: * other cancer diagnosis for the past three years, except for non-melanoma skin cancer * prior chemotherapy within the last three years; radiation therapy to the pelvis or prior pelvic surgery within the past three years * prior neoadjuvant therapy, such as hormones (Bicalutamide use for less than or equal to 1 month would not constitute exclusion from study entry) For the cross-sectional component of the study, all patients identified to be free of disease at least ten years post -treatment will be considered eligible. Patients must have no clinical evidence of local, regional or distant recurrences. Patients must have the ability to read and understand English. Patients who received hormonal therapy will be eligible for the cross-sectional component of the study, but the duration of the hormonal therapy must be six months or less. the investigators have identified a cohort of patients who fit these criteria from our databases.
References
Publications (0)
Data not yet available